University of California San Francisco
Give to UCSFA hepatitis outbreak in children occurred after COVID-19 lockdowns eased in 2022. Sudden exposure to a multitude of viruses upon reopening may have triggered this response in a small group of children.
Thermo Fisher Scientific Inc. and UCSF will accelerate advanced cell therapies for difficult to treat conditions like cancer from a new manufacturing facility.
A clinical trial showed that, rather than removing lymph nodes, leaving them intact could help immunotherapy activate tumor-fighting T cells in the lymph nodes.
A sexual health strategy called Doxy-PEP, which involves taking doxycycline after condomless sex, is highly effective in reducing bacterial STIs but is still associated with a limited rise in resistant strains of bacteria.
Respiratory viral infections pose significant morbidity and mortality to patients with chronic lung diseases like emphysema and COPD, causing exacerbations that drive destruction of normal lung tissue
UCSF researchers found that distributing pro-COVID-19 vaccine information in EDs in English and Spanish increased vaccine acceptance, especially among Latinos and those without primary care physicians.
Balyn Zaro’s lab investigates the cause and consequence of genetic diversity in the immune system, in hopes that her discoveries can lead to better treatments for all patients.
When we inhale an airborne virus, our lung cells take on the role of immune system first responders. Catera Wilder, PhD, studies the molecular details of this response and how it can go awry, causing the body to damage its own tissue and cells.
Emily Goldberg's lab studies what happens during aging to a particular set of immune cells: those embedded in fat tissue. She hypothesizes that changes to these cells during aging could be key to age-related inflammation.
Angela Phillips, PhD, leads research that could help predict future viruses like COVID and the antibodies we might use to treat them.
Researchers have genetically engineered cells to distract antibodies from attacking friendly, but foreign, cells. This could prevent transplants from being rejected.
California prisons saw more than 20,000 COVID-19 Omicron cases over a five-month period. However, vaccination and boosting kept hospitalization and death rates low.
The California Collaborative for Pandemic Recovery and Readiness Research (CPR3) at UCSF will investigate the effects of the pandemic on California communities and individuals.
T-cells can be directed to produce cytokine, a powerful anti-cancer component, when they encounter cancer cells. This holds tremendous promise for cancer immunotherapy.
Risk of death or hospitalization from COVID-19 were found to be greater for patients with PTSD.
Researchers have identified specific immune cells that drive deadly heart inflammation in a small fraction of patients treated with powerful cancer immunotherapy drugs.
A new method of comparing massive numbers of CAR-T cells can determine which is most effective and long-lasting against cancer.
Immune checkpoint inhibitors (ICIs) used in cancer care can cause myocarditis, a potentially fatal side effect, and it appears that the adverse cardiac effects may disproportionally impact female patients.
A new diagnostic method that applies machine learning to advanced genomics data from both microbe and host to identify and predict sepsis cases was developed by researchers at UCSF, the Chan Zuckerberg Initiative, and CZ Biohub.
Scientists at UCSF have developed a new way of looking at sex-biased diseases that is rooted in evolutionary biology.
A new study points to another persistent effect of COVID-19, identified months after infection: reduced exercise capacity.
Last month new “bivalent” booster vaccines made by Moderna and Pfizer became available that protect against currently circulating Omicron variants as well as earlier strains of the SARS-CoV-2 virus that causes COVID-19. This Q&A features Joel Ernst, MD, a UCSF professor of medicine whose research aims to understand how pathogens evade the immune system.